Therapy of acute myeloid leukemia: therapeutic targeting of tyrosine kinases.
Joseph CioccioDavid F ClaxtonPublished in: Expert opinion on investigational drugs (2019)
The use of TKIs in the clinic is improving outcomes for many patients. An improved understanding of tyrosine kinase biology and the expanding use of TKIs are likely to dramatically improve outcomes in the coming decade. TKIs and other targeted agents could gradually supplant the use of cytotoxic chemotherapy for AML.
Keyphrases
- tyrosine kinase
- acute myeloid leukemia
- end stage renal disease
- chronic kidney disease
- ejection fraction
- cancer therapy
- allogeneic hematopoietic stem cell transplantation
- prognostic factors
- peritoneal dialysis
- stem cells
- type diabetes
- adipose tissue
- patient reported outcomes
- skeletal muscle
- mesenchymal stem cells
- bone marrow
- drug delivery
- weight loss
- rectal cancer
- insulin resistance
- chemotherapy induced